Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 400 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.topiramate teva is indicated in adults for the prevention of migraines. the use of topiramate teva in the acute treatment of migraine has not been studied .

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - topiramate - tablets - topiramate 400 mg - topiramate - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - flunitrazepam - tablets - flunitrazepam 2 mg - flunitrazepam - flunitrazepam - insomnia of various etiology.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - mirtazapine - tablets - mirtazapine 30 mg - mirtazapine - mirtazapine - episode of major depression.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - mirtazapine - tablets - mirtazapine 30 mg - mirtazapine - mirtazapine - episode of major depression.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - mirtazapine - tablets - mirtazapine 45 mg - mirtazapine - mirtazapine - episode of major depression.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - mirtazapine - tablets - mirtazapine 45 mg - mirtazapine - mirtazapine - episode of major depression.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient. for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute co